^
Association details:
| Biomarker: | CEACAM5 expression |
|---|---|
| Cancer: | Neuroendocrine Tumor |
| Drug: | labetuzumab govitecan (IMMU-130) (Topoisomerase I inhibitor, CEACAM5-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Regulation of CEACAM5 and therapeutic efficacy of an anti-CEACAM5-SN38 antibody-drug conjugate in neuroendocrine prostate cancer
Published date:
11/16/2020
Excerpt:
Labetuzumab govitecan induced DNA damage in CEACAM5+ prostate cancer cell lines and marked antitumor responses in CEACAM5+ CRPC xenograft models including chemotherapy-resistant NEPC.
DOI:
10.1158/1078-0432.CCR-20-3396
